ArticleScience advances2023

Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.

Daniel Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.